trial · primary record
ALA-101
Non Hodgkin Lymphoma (NHL)
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 46 |
| Primary completion | 2030-08-30 |
| Primary endpoint | To evaluate the safety and tolerability of ALA-101 in adult participants with CD19+ NonHodgkin Lymphoma (NHL) and CD19+ leukemia |
| Registry ID | NCT07518329 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:07.567Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07518329
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.